NCT04532281

Clinical Trial for the Safety and Efficacy of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Study Summary

A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.

Interested in this trial?

Submit an Inquiry

Murine CD19 CAR-T cellsDRUG

Each subject receive murine CD19 CAR T-cells by intravenous infusion

Facility	City	State	Country
The First Affiliated Hospital，College of Medicine, Zhejiang University	Hangzhou	Zhejiang	China

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026